Genovis AB (Sweden) Today
| GENO Stock | SEK 28.05 0.85 3.13% |
Performance2 of 100
| Odds Of DistressLess than 9
|
Genovis AB is selling for under 28.05 as of the 25th of November 2024; that is 3.13% up since the beginning of the trading day. The stock's last reported lowest price was 27.1. Genovis AB has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Genovis AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of December 2022 and ending today, the 25th of November 2024. Click here to learn more.
Genovis AB develops, produces, and sells tools for developing new medications and diagnostics for customers in the medical device and pharmaceutical industries. Genovis AB was founded in 1999 and is based in Lund, Sweden. Genovis AB operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. The company has 65.47 M outstanding shares. More on Genovis AB
Moving against Genovis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genovis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genovis AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genovis AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Genovis AB (GENO) is traded on Stockholm Exchange in Sweden and employs 37 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genovis AB's market, we take the total number of its shares issued and multiply it by Genovis AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genovis AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 65.47 M outstanding shares.
Genovis AB has accumulated about 81.31 M in cash with 45.92 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Check Genovis AB Probability Of Bankruptcy
Ownership AllocationGenovis AB has a total of 65.47 Million outstanding shares. Genovis AB secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genovis Ownership Details
Genovis AB Risk Profiles
Although Genovis AB's alpha and beta are two of the key measurements used to evaluate Genovis AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.66 | |||
| Semi Deviation | 2.41 | |||
| Standard Deviation | 4.74 | |||
| Variance | 22.44 |
Genovis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genovis AB without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Genovis AB Corporate Management
Elected by the shareholders, the Genovis AB's board of directors comprises two types of representatives: Genovis AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genovis. The board's role is to monitor Genovis AB's management team and ensure that shareholders' interests are well served. Genovis AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genovis AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susanne Ahlberg | G Counsel | Profile | |
| BA BA | Pres Inc | Profile | |
| Magnus Langberg | Group Officer | Profile | |
| Maria Edholm | Controller | Profile | |
| Fredrik Olsson | Pres CEO | Profile | |
| Linda Andersson | VP Production | Profile | |
| Rikke Rytter | VP Marketing | Profile |
Additional Tools for Genovis Stock Analysis
When running Genovis AB's price analysis, check to measure Genovis AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genovis AB is operating at the current time. Most of Genovis AB's value examination focuses on studying past and present price action to predict the probability of Genovis AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genovis AB's price. Additionally, you may evaluate how the addition of Genovis AB to your portfolios can decrease your overall portfolio volatility.